

APPOINTMENT OF EXECUTIVE DIRECTOR & UPDATE ON FDA PRE-IND MEETING

NeuroScientific Biopharmaceuticals Ltd (**ASX:NSB**) (“**NeuroScientific**” or “**the Company**”) is pleased to advise that the Company has filed a Pre-Investigation New Drug Application (‘pre-IND’) meeting request with the US Food and Drug Administration (‘FDA’) for EmtinB for treatment of advanced glaucoma in adults. The request includes an overview of the proposed non-clinical and clinical programs in glaucoma, as well as specific questions relating to regulatory requirements for progression to the filing of an investigational new drug (‘IND’) application. NeuroScientific expects the meeting to be held within 60 days.

Additionally, and following the filing, current Non-executive Director, Dr Tony Keating was appointed as Executive Director of the Company, to commence initially on a part time basis which followed the resignation of Dougal Thring as chief operating officer. Dr Keating was first appointed as Director of the Company on 5 December 2023 and is an experienced entrepreneur and CEO having co-founded and led ResApp Health from start-up to its ultimate acquisition by Pfizer for \$180 million.

NeuroScientific Chairman, Chris Ntoumenopoulos said “We are extremely pleased that Dr Keating has stepped up to the role of Executive Director. Tony has a proven track record having successfully led ResApp which he co-founded to being acquired by Pfizer for \$180 million in 2022. Following the sale, Tony took on the role of Vice President at Pfizer leading the integration of ResApp’s business in Pfizer. Not only is Dr Keating extremely respected in the industry, but his international network is second to none.

Importantly, discussing with the FDA the use of EmtinB to treat advanced glaucoma will provide clarity around our planned non-clinical and clinical glaucoma program, leading us closer to submission of an IND application and our first-in-human studies targeting glaucoma in the US. We are grateful for Tony transitioning into an executive role and providing a safe pair of hands as we progress towards submission. Lastly, the Board would like to thank Dougal for his time and wish him all the best in his future endeavours.”

Dr Keating will be paid \$40,000 per annum based on an initially agreed 20% FTE basis in addition to director fees of \$50,000 per annum (ASX Announcement dated 5 December 2023). There is no fixed term, and a 2-month notice period. Short term and long-term incentives will be provided but are yet to be determined and will require shareholder approval. Dr Keating’s executive service agreement contains otherwise standard terms and conditions for an agreement of this nature, including confidentiality, retention, intellectual property and leave.

This announcement is authorised by the board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Chris Ntoumenopoulos
Chairman
ir@neuroscientific.com
+ 61 8 6382 1805